According to Future Market Insights research, during the projected period, the global prostate-specific antigen (PSA) testing market is expected to grow at a CAGR of 12.0%. The market value is projected to increase from US$ 6.3 Billion in 2023 to US$ 19.5 billion by 2033. The global prostate-specific antigen (PSA) testing market was valued at US$ 5.7 billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 11.1% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 5.7 Billion |
| Market Value 2023 | US$ 6.3 Billion |
| Market Value 2033 | US$ 19.5 Billion |
| CAGR 2023 to 2033 | 12.0% |
| Share of Top 5 Countries | 60.1% |
| Key Players | The key players in the Prostate-Specific Antigen (PSA) Testing Market Are Xiamen Biotime Biotechnology Co.; Ltd.; HWTAi; OptiBio Co.; Ltd; Jiangsu MicroDiag Biomedicine Technology Co.; Ltd.; Beijing Hotgen Biotechn Co.; Ltd; Humasis; Accuquik™ Test Kits; CTK Biotech; Inc; INTEC; XIAMEN BOSON BIOTECH CO.; LTD; AccuBioTech Co.; Ltd.; Bio-Rad Laboratories; Inc.; Accuquik Test Kits; OPKO Health; Inc.; bioMérieux SA; Beckman Coulter; Inc.; Abbott; Siemens Healthcare; DiaSorin ; Roche; Mediwatch (LABORIE); BodiTech; Bristol-Myers Squibb Company; GE Healthcare; Endocare ; GlaxoSmithKline; Anixa Biosciences; Ortho Clinical ; Fujirebio; Pharmacia Delfia |
A crucial tumor marker for prostate cancer, prostate specific antigen (PSA), is a type of protein that is only released by certain cells. Although it is not a chemical specific to the prostate, its increased presence in blood serum is used to identify males with prostate cancer. A digital rectal exam (DRE) and PSA tests are used to check for prostate cancer in asymptomatic men. Clinicians and healthcare professionals now, frequently use PSA screening to look for potential prostate cancer cases to help them understand the nature of the issue.
Both healthy and cancerous cells of the prostate gland generate the PSA protein, which is exclusive to the prostate. A blood sample is sent to a lab for analysis as part of the PSA test, which gauges the level of PSA in the body. PSA levels in blood are often measured in nanograms (ng/mL).
Some organizations do advise starting PSA testing at age 40 or 45 for men who have a higher chance of developing prostate cancer. Males of color, those with BRCA2 germline variations (and, to a lesser extent, BRCA1 variants), and males whose father or brother had prostate cancer are among those at risk.
Overall, the increasing adoption of latest technologies and new product launches such as Compared to the presently utilized prostate-specific antigen (PSA) blood test, the prostate screening EpiSwitch (PSE) blood test is more than 90 percent accurate. this factors will boost the market in the coming years.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the prostate-specific antigen (PSA) testing market grew at a CAGR of 9.9% between 2018 and 2022. Prostate-specific antigen (PSA) testing market contributes 3.4% revenue share to the cancer diagnostics market valued at US$ 166.2 Billion in 2022.
In order to monitor the progression of prostate cancer in men who had already received a diagnosis, the FDA originally authorized the PSA test in 1986. Patients with prostate cancer usually have increased PSA levels in their blood. In year 1994, the FDA approved the combination of PSA test with DRE to aid in the diagnosis of prostate cancer.
As more information about the advantages and disadvantages of prostate cancer screening became available starting about 2008, a number of professional medical organizations started to issue warnings against the PSA test's widespread use in population screening. The majority of organizations advise those who are thinking about PSA screening to first go over the advantages and disadvantages with their doctors.
Prostate explicit antigen testing market is driving ahead a result of expansion in geriatric population. Additionally, the growth of the prostate specific antigen market is influenced by technological advancements in prostate cancer testing and treatment, as well as a number of reimbursement policies for prostate cancer treatment in both developed and developing countries.
Creating awareness about diseases is an essential aspect of early detection and screening. If the public has a general understanding of diseases and symptoms, action plans can be better implemented. On the other hand, if there is a lack of awareness, it stops people from taking preventive measures or availing treatments.
Considering this, FMI expects the prostate-specific antigen (PSA) testing market to grow at a CAGR of 12.0% through the forecasted years.
The rising prevalence of prostate cancer in men, particularly among those over 50, is driving the global market for prostate-specific specific antigen testing. After treatment for prostate cancer, PSA levels must also be checked on a regular basis.
New item dispatches and new technological advancements are open doors for development in the market.
A few reimbursement strategies in different created and creating locales cover yearly public service announcement testing among men with age at least 50. Besides, public service announcement testing being incorporated as a piece of the yearly wellbeing inclusion in created countries like USA is supposed to set out promising open doors for market players. These factors are expected to provide growth opportunities to key players in the market over the forecast period.
Principal Consultant
Prostate explicit antigen testing market need to confront a few difficult circumstances due to the misleading positive or bogus adverse consequences of public service announcement test. Additionally, activities like public service announcement screening had a great deal of secondary effects, for example, troubles in progression of pee, consequences for working of entrails, erectile brokenness and successive torments alongside bogus outcomes; subsequently blocking the development of prostate explicit antigen testing market.
Higher improvement in the innovation resulting in most streamlined and exact outcomes in the tests like prostate wellbeing file (phi) can lessen the development in public service announcement testing market except if there is an adjustment of how the tests are dealt with.
Over determination of clinically immaterial prostate malignant growth, combined with exaggeration of the outcomes is a significant hindrance in the reception of public service announcement testing.
These factors are expected to hamper revenue growth of the prostate-specific antigen (PSA) testing market over the forecast period.
In United States, prostate cancer is the most common malignancy among men, except from skin cancer.
During the projected period, the market for prostate-specific antigen (PSA) testing in the United States is anticipated to grow at a CAGR of 10.2%.
Due to the high prevalence of prostate cancer diagnostic methods will be in demand for prostate-specific antigen testing, which will drive the expansion of the market.
Germany dominated the European market for prostate-specific antigen (PSA) testing market and accounted for around 29.8% of the market share in 2022.
Recent investigations by University of East Anglia’, Europe, have shown that the prostate screening blood test EpiSwitch (PSE) is more accurate than the currently used PSA blood test by more than 90%. The new test provides an accurate and speedy cancer screening diagnosis, according to the study team. The PSE test offers a rapid, minimally invasive prostate cancer detection and has exceptional effectiveness when used to screen a population at risk.
Over the years, due to growing number of research activities to develop new testing options in prostate cancer testing, Germany market for PSA testing will grow.
The safe and successful use PSA testing in Germany will influence other European countries to also opt for this method, ultimately expanding the overall market.
China is projected to be the most attractive market in the East Asia prostate-specific antigen (PSA) testing market and is expected to grow over a significant CAGR of 11.2%.
The growing public and professional awareness of the condition is one of the main factors influencing the growth of the prostate-specific antigen (PSA) testing market in China.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Immunoassay segment held the major chunk of about 56.8% in global market by the end of 2022.
Many of infectious diseases require rapid diagnosis that’s where prostate-specific antigen (PSA) testing market diagnostics plays a significant role.
Prostate-specific antigen (PSA) testing involves testing type such as immunoassays, ELISA kits, lateral flow assays, chemiluminescent immunoassays (CLIAs), radioimmunoassay, point-of-care testing kits, cassette/cards, strips. However, Immunoassay testing is preferred over POCT because immunoassays have more specificity and more reliable results.
Overall, PSA test is used for detection of prostate-specific antigen due to their high specificity.
Whole blood segment accounted for revenue share of 52.4% in the global market at the end of 2022.
Complete blood count tests are frequently advised by doctors to track patient’s health. This blood test can be used in cancer therapy to aid in the diagnosis of a malignancy or to track how the disease or its treatment is impacting the patient's body.
Overall, whole blood offers a convenient sample type for prostate-specific antigen (PSA) testing market treating products, making it the most significant sample for this segment.
Hospitals segment accounted for revenue share of 44.1% in the global market at the end of 2022.
Hospitals have availability of testing kits and hospitals are main source of blood sample withdrawing channel for prostate-specific antigen (PSA) testing.
Overall, hospitals offers a convenient testing options for prostate-specific antigen (PSA) testing, making it the dominant end user for this segment.
The prostate-specific antigen (PSA) testing market's major companies are concentrating on diversifying their product offerings to boost their market share and establish a presence in developing nations. Pricing strategies, market strategies, technology improvements, regulatory compliance, and acquisition and distribution agreements with other firms to extend their company are the main tactics used by manufacturers to acquire a competitive advantage in the market.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Prostate-specific Antigen (PSA) Testing market space, which are available in the full report
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries |
| Key Segments Covered | Test Type, Sample Type, End User, Region |
| Key Companies Profiled | Xiamen Biotime Biotechnology Co., Ltd.; HWTAi; OptiBio Co., Ltd; Jiangsu MicroDiag Biomedicine Technology Co., Ltd.; Beijing Hotgen Biotechn Co., Ltd; Humasis, Accuquik™ Test Kits; CTK Biotech, Inc.; INTEC; XIAMEN BOSON BIOTECH CO., LTD; AccuBioTech Co., Ltd.; Bio-Rad Laboratories, Inc.; Accuquik Test Kits; OPKO Health, Inc.; bioMérieux SA; Beckman Coulter, Inc.; Abbott; Siemens Healthcare; DiaSorin; F. Hoffmann-La Roche Ltd; Mediwatch (LABORIE); BodiTech; Bristol-Myers Squibb Company; GE Healthcare; Endocare; GlaxoSmithKline; Anixa Biosciences; Ortho Clinical; Fujirebio; Pharmacia Delfia |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Aging populations and prostate cancer awareness influencing the market growth.
Asia Pacific is expanding quickly because of better healthcare infrastructure.
Laboratory-based PSA testing segment occupies a dominant position in the market.
The rising incidence of prostate cancer and improvements in diagnostic technology.
The North America has seen significant adoption of PSA testing on a global scale.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Key Success Factors 4.1. Product Adoption Analysis 4.2. Regulatory Scenario 4.3. Reimbursement Landscape 4.4. PESTLE Analysis 4.5. Porter’s Analysis 4.6. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global IVD Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increasing Treatment Seeking Rate 5.2.3. New Test Type Launches/Approvals 5.2.4. Increasing Incidence of Prostate Cancer 5.2.5. Government Initiatives to Combat Prostate Cancer 5.2.6. Companies Increasingly Spending on R&D and Focus on Innovation 5.2.7. Collaborations and Agreements between Manufacturers 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis - Impact Assessment 6.1. COVID-19 and Impact Analysis 6.1.1. By Test Type 6.1.2. By Sample Type 6.1.3. By End User 6.2. 2022 Market Scenario 7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033 8.3.1. Immunoassays 8.3.1.1. ELISA kits 8.3.1.2. Lateral flow assays 8.3.1.3. Chemiluminescent immunoassays (CLIAs) 8.3.1.4. Radioimmunoassay 8.3.2. Kits 8.3.2.1. Cassette/Cards 8.3.2.2. Strips 8.4. Market Attractiveness Analysis by Test Type 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sample Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis by Sample Type, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) and Forecast by Sample Type, 2023 to 2033 9.3.1. Whole Blood 9.3.2. Serum 9.3.3. Plasma 9.4. Market Attractiveness Analysis by Sample Type 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By End User, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 10.3.1. Hospitals 10.3.2. Diagnostics laboratories 10.3.3. Specialty Clinics 10.3.4. Research Institutes 10.3.5. Others 10.4. Market Attractiveness Analysis by End User 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. Middle East & Africa 11.4. Market Attractiveness Analysis By Country 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Test Type 12.3.3. By Sample Type 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Test Type 12.4.3. By Sample Type 12.4.4. By End User 12.5. Market Trends 12.6. Key Market Participant - Intensity Mapping 12.7. Drivers & Restraints Impact Analysis 12.8. Country-wise Analysis 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Test Type 12.8.1.2.2. By Sample Type 12.8.1.2.3. By End User 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Test Type 12.8.2.2.2. By Sample Type 12.8.2.2.3. By End User 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Test Type 13.3.3. By Sample Type 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Test Type 13.4.3. By Sample Type 13.4.4. By End User 13.5. Market Trends 13.6. Key Market Participant - Intensity Mapping 13.7. Drivers & Restraints Impact Analysis 13.8. Country-wise Analysis 13.8.1. Brazil Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Test Type 13.8.1.2.2. By Sample Type 13.8.1.2.3. By End User 13.8.2. Mexico Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Test Type 13.8.2.2.2. By Sample Type 13.8.2.2.3. By End User 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Test Type 13.8.3.2.2. By Sample Type 13.8.3.2.3. By End User 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. UK 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Test Type 14.3.3. By Sample Type 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Test Type 14.4.3. By Sample Type 14.4.4. By End User 14.5. Market Trends 14.6. Key Market Participant - Intensity Mapping 14.7. Drivers & Restraints Impact Analysis 14.8. Country-wise Analysis 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Test Type 14.8.1.2.2. By Sample Type 14.8.1.2.3. By End User 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Test Type 14.8.2.2.2. By Sample Type 14.8.2.2.3. By End User 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Test Type 14.8.3.2.2. By Sample Type 14.8.3.2.3. By End User 14.8.4. UK Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Test Type 14.8.4.2.2. By Sample Type 14.8.4.2.3. By End User 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Test Type 14.8.5.2.2. By Sample Type 14.8.5.2.3. By End User 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Test Type 14.8.6.2.2. By Sample Type 14.8.6.2.3. By End User 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Test Type 14.8.7.2.2. By Sample Type 14.8.7.2.3. By End User 15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Malaysia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Test Type 15.3.3. By Sample Type 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Test Type 15.4.3. By Sample Type 15.4.4. By End User 15.5. Market Trends 15.6. Key Market Participant - Intensity Mapping 15.7. Drivers & Restraints Impact Analysis 15.8. Country-wise Analysis 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Test Type 15.8.1.2.2. By Sample Type 15.8.1.2.3. By End User 15.8.2. Indonesia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Test Type 15.8.2.2.2. By Sample Type 15.8.2.2.3. By End User 15.8.3. Malaysia Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Test Type 15.8.3.2.2. By Sample Type 15.8.3.2.3. By End User 15.8.4. Thailand Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Test Type 15.8.4.2.2. By Sample Type 15.8.4.2.3. By End User 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Test Type 16.3.3. By Sample Type 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Test Type 16.4.3. By Sample Type 16.4.4. By End User 16.5. Market Trends 16.6. Key Market Participant - Intensity Mapping 16.7. Drivers & Restraints Impact Analysis 16.8. Country-wise Analysis 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Test Type 16.8.1.2.2. By Sample Type 16.8.1.2.3. By End User 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Test Type 16.8.2.2.2. By Sample Type 16.8.2.2.3. By End User 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Test Type 16.8.3.2.2. By Sample Type 16.8.3.2.3. By End User 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Test Type 17.3.3. By Sample Type 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Test Type 17.4.3. By Sample Type 17.4.4. By End User 17.5. Market Trends 17.6. Key Market Participant - Intensity Mapping 17.7. Drivers & Restraints Impact Analysis 17.8. Country-wise Analysis 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Test Type 17.8.1.2.2. By Sample Type 17.8.1.2.3. By End User 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Test Type 17.8.2.2.2. By Sample Type 17.8.2.2.3. By End User 18. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Country 18.3.1.2. Turkey 18.3.1.3. South Africa 18.3.1.4. North Africa 18.3.1.5. Rest of MEA 18.3.2. By Test Type 18.3.3. By Sample Type 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Test Type 18.4.3. By Sample Type 18.4.4. By End User 18.5. Market Trends 18.6. Key Market Participant - Intensity Mapping 18.7. Drivers & Restraints Impact Analysis 18.8. Country-wise Analysis 18.8.1. GCC Country Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Test Type 18.8.1.2.2. By Sample Type 18.8.1.2.3. By End User 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Test Type 18.8.2.2.2. By Sample Type 18.8.2.2.3. By End User 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Test Type 18.8.3.2.2. By Sample Type 18.8.3.2.3. By End User 18.8.4. North South Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Test Type 18.8.4.2.2. By Sample Type 18.8.4.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Concentration 19.4. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Key Development Analysis 20.3. Branding and Promotional Strategies, By Key Players 20.4. Competition Deep Dive 20.4.1. Xiamen Biotime Biotechnology Co. Ltd. 20.4.1.1. Overview 20.4.1.2. Product Portfolio 20.4.1.3. Key Financials 20.4.1.4. SWOT Analysis 20.4.1.5. Key Developments 20.4.1.6. Sales Footprint 20.4.1.7. Strategy Overview 20.4.1.7.1. Marketing Strategy 20.4.1.7.2. Product Strategy 20.4.1.7.3. Channel Strategy 20.4.2. HWTAi, 20.4.2.1. Overview 20.4.2.2. Product Portfolio 20.4.2.3. Key Financials 20.4.2.4. SWOT Analysis 20.4.2.5. Key Developments 20.4.2.6. Sales Footprint 20.4.2.7. Strategy Overview 20.4.2.7.1. Marketing Strategy 20.4.2.7.2. Product Strategy 20.4.2.7.3. Channel Strategy 20.4.3. OptiBio Co., Ltd 20.4.3.1. Overview 20.4.3.2. Product Portfolio 20.4.3.3. Key Financials 20.4.3.4. SWOT Analysis 20.4.3.5. Key Developments 20.4.3.6. Sales Footprint 20.4.3.7. Strategy Overview 20.4.3.7.1. Marketing Strategy 20.4.3.7.2. Product Strategy 20.4.3.7.3. Channel Strategy 20.4.4. Jiangsu MicroDiag Biomedicine Technology Co., Ltd. 20.4.4.1. Overview 20.4.4.2. Product Portfolio 20.4.4.3. Key Financials 20.4.4.4. SWOT Analysis 20.4.4.5. Key Developments 20.4.4.6. Sales Footprint 20.4.4.7. Strategy Overview 20.4.4.7.1. Marketing Strategy 20.4.4.7.2. Product Strategy 20.4.4.7.3. Channel Strategy 20.4.5. Beijing Hotgen Biotechn Co., Ltd 20.4.5.1. Overview 20.4.5.2. Product Portfolio 20.4.5.3. Key Financials 20.4.5.4. SWOT Analysis 20.4.5.5. Key Developments 20.4.5.6. Sales Footprint 20.4.5.7. Strategy Overview 20.4.5.7.1. Marketing Strategy 20.4.5.7.2. Product Strategy 20.4.5.7.3. Channel Strategy 20.4.6. Humasis, Accuquik™ Test Kits 20.4.6.1. Overview 20.4.6.2. Product Portfolio 20.4.6.3. Key Financials 20.4.6.4. SWOT Analysis 20.4.6.5. Key Developments 20.4.6.6. Sales Footprint 20.4.6.7. Strategy Overview 20.4.6.7.1. Marketing Strategy 20.4.6.7.2. Product Strategy 20.4.6.7.3. Channel Strategy 20.4.7. CTK Biotech, Inc 20.4.7.1. Overview 20.4.7.2. Product Portfolio 20.4.7.3. Key Financials 20.4.7.4. SWOT Analysis 20.4.7.5. Key Developments 20.4.7.6. Sales Footprint 20.4.7.7. Strategy Overview 20.4.7.7.1. Marketing Strategy 20.4.7.7.2. Product Strategy 20.4.7.7.3. Channel Strategy 20.4.8. INTEC 20.4.8.1. Overview 20.4.8.2. Product Portfolio 20.4.8.3. Key Financials 20.4.8.4. SWOT Analysis 20.4.8.5. Key Developments 20.4.8.6. Sales Footprint 20.4.8.7. Strategy Overview 20.4.8.7.1. Marketing Strategy 20.4.8.7.2. Product Strategy 20.4.8.7.3. Channel Strategy 20.4.9. XIAMEN BOSON BIOTECH CO., LTD 20.4.9.1. Overview 20.4.9.2. Product Portfolio 20.4.9.3. Key Financials 20.4.9.4. SWOT Analysis 20.4.9.5. Key Developments 20.4.9.6. Sales Footprint 20.4.9.7. Strategy Overview 20.4.9.7.1. Marketing Strategy 20.4.9.7.2. Product Strategy 20.4.9.7.3. Channel Strategy 20.4.10. AccuBioTech Co., Ltd. 20.4.10.1. Overview 20.4.10.2. Product Portfolio 20.4.10.3. Key Financials 20.4.10.4. SWOT Analysis 20.4.10.5. Key Developments 20.4.10.6. Sales Footprint 20.4.10.7. Strategy Overview 20.4.10.7.1. Marketing Strategy 20.4.10.7.2. Product Strategy 20.4.10.7.3. Channel Strategy 20.4.11. Bio-Rad Laboratories, Inc. 20.4.11.1. Overview 20.4.11.2. Product Portfolio 20.4.11.3. Key Financials 20.4.11.4. SWOT Analysis 20.4.11.5. Key Developments 20.4.11.6. Sales Footprint 20.4.11.7. Strategy Overview 20.4.11.7.1. Marketing Strategy 20.4.11.7.2. Product Strategy 20.4.11.7.3. Channel Strategy 20.4.12. Accuquik Test Kits 20.4.12.1. Overview 20.4.12.2. Product Portfolio 20.4.12.3. Key Financials 20.4.12.4. SWOT Analysis 20.4.12.5. Key Developments 20.4.12.6. Sales Footprint 20.4.12.7. Strategy Overview 20.4.12.7.1. Marketing Strategy 20.4.12.7.2. Product Strategy 20.4.12.7.3. Channel Strategy 20.4.13. OPKO Health, Inc. 20.4.13.1. Overview 20.4.13.2. Product Portfolio 20.4.13.3. Key Financials 20.4.13.4. SWOT Analysis 20.4.13.5. Key Developments 20.4.13.6. Sales Footprint 20.4.13.7. Strategy Overview 20.4.13.7.1. Marketing Strategy 20.4.13.7.2. Product Strategy 20.4.13.7.3. Channel Strategy 20.4.14. bioMérieux SA 20.4.14.1. Overview 20.4.14.2. Product Portfolio 20.4.14.3. Key Financials 20.4.14.4. SWOT Analysis 20.4.14.5. Key Developments 20.4.14.6. Sales Footprint 20.4.14.7. Strategy Overview 20.4.14.7.1. Marketing Strategy 20.4.14.7.2. Product Strategy 20.4.14.7.3. Channel Strategy 20.4.15. Beckman Coulter, Inc 20.4.15.1. Overview 20.4.15.2. Product Portfolio 20.4.15.3. Key Financials 20.4.15.4. SWOT Analysis 20.4.15.5. Key Developments 20.4.15.6. Sales Footprint 20.4.15.7. Strategy Overview 20.4.15.7.1. Marketing Strategy 20.4.15.7.2. Product Strategy 20.4.15.7.3. Channel Strategy 20.4.16. Abbott 20.4.16.1. Overview 20.4.16.2. Product Portfolio 20.4.16.3. Key Financials 20.4.16.4. SWOT Analysis 20.4.16.5. Key Developments 20.4.16.6. Sales Footprint 20.4.16.7. Strategy Overview 20.4.16.7.1. Marketing Strategy 20.4.16.7.2. Product Strategy 20.4.16.7.3. Channel Strategy 20.4.17. Siemens Healthcare 20.4.17.1. Overview 20.4.17.2. Product Portfolio 20.4.17.3. Key Financials 20.4.17.4. SWOT Analysis 20.4.17.5. Key Developments 20.4.17.6. Sales Footprint 20.4.17.7. Strategy Overview 20.4.17.7.1. Marketing Strategy 20.4.17.7.2. Product Strategy 20.4.17.7.3. Channel Strategy 20.4.18. DiaSorin 20.4.18.1. Overview 20.4.18.2. Product Portfolio 20.4.18.3. Key Financials 20.4.18.4. SWOT Analysis 20.4.18.5. Key Developments 20.4.18.6. Sales Footprint 20.4.18.7. Strategy Overview 20.4.18.7.1. Marketing Strategy 20.4.18.7.2. Product Strategy 20.4.18.7.3. Channel Strategy 20.4.19. F. Hoffmann-La Roche Ltd 20.4.19.1. Overview 20.4.19.2. Product Portfolio 20.4.19.3. Key Financials 20.4.19.4. SWOT Analysis 20.4.19.5. Key Developments 20.4.19.6. Sales Footprint 20.4.19.7. Strategy Overview 20.4.19.7.1. Marketing Strategy 20.4.19.7.2. Product Strategy 20.4.19.7.3. Channel Strategy 20.4.20. Mediwatch (LABORIE) 20.4.20.1. Overview 20.4.20.2. Product Portfolio 20.4.20.3. Key Financials 20.4.20.4. SWOT Analysis 20.4.20.5. Key Developments 20.4.20.6. Sales Footprint 20.4.20.7. Strategy Overview 20.4.20.7.1. Marketing Strategy 20.4.20.7.2. Product Strategy 20.4.20.7.3. Channel Strategy 20.4.21. BodiTech 20.4.21.1. Overview 20.4.21.2. Product Portfolio 20.4.21.3. Key Financials 20.4.21.4. SWOT Analysis 20.4.21.5. Key Developments 20.4.21.6. Sales Footprint 20.4.21.7. Strategy Overview 20.4.21.7.1. Marketing Strategy 20.4.21.7.2. Product Strategy 20.4.21.7.3. Channel Strategy 20.4.22. Bristol-Myers Squibb Company 20.4.22.1. Overview 20.4.22.2. Product Portfolio 20.4.22.3. Key Financials 20.4.22.4. SWOT Analysis 20.4.22.5. Key Developments 20.4.22.6. Sales Footprint 20.4.22.7. Strategy Overview 20.4.22.7.1. Marketing Strategy 20.4.22.7.2. Product Strategy 20.4.22.7.3. Channel Strategy 20.4.23. GE Healthcare 20.4.23.1. Overview 20.4.23.2. Product Portfolio 20.4.23.3. Key Financials 20.4.23.4. SWOT Analysis 20.4.23.5. Key Developments 20.4.23.6. Sales Footprint 20.4.23.7. Strategy Overview 20.4.23.7.1. Marketing Strategy 20.4.23.7.2. Product Strategy 20.4.23.7.3. Channel Strategy 20.4.24. Endocare 20.4.24.1. Overview 20.4.24.2. Product Portfolio 20.4.24.3. Key Financials 20.4.24.4. SWOT Analysis 20.4.24.5. Key Developments 20.4.24.6. Sales Footprint 20.4.24.7. Strategy Overview 20.4.24.7.1. Marketing Strategy 20.4.24.7.2. Product Strategy 20.4.24.7.3. Channel Strategy 20.4.25. GlaxoSmithKline 20.4.25.1. Overview 20.4.25.2. Product Portfolio 20.4.25.3. Key Financials 20.4.25.4. SWOT Analysis 20.4.25.5. Key Developments 20.4.25.6. Sales Footprint 20.4.25.7. Strategy Overview 20.4.25.7.1. Marketing Strategy 20.4.25.7.2. Product Strategy 20.4.25.7.3. Channel Strategy 20.4.26. Anixa Biosciences 20.4.26.1. Overview 20.4.26.2. Product Portfolio 20.4.26.3. Key Financials 20.4.26.4. SWOT Analysis 20.4.26.5. Key Developments 20.4.26.6. Sales Footprint 20.4.26.7. Strategy Overview 20.4.26.7.1. Marketing Strategy 20.4.26.7.2. Product Strategy 20.4.26.7.3. Channel Strategy 20.4.27. Ortho Clinical 20.4.27.1. Overview 20.4.27.2. Product Portfolio 20.4.27.3. Key Financials 20.4.27.4. SWOT Analysis 20.4.27.5. Key Developments 20.4.27.6. Sales Footprint 20.4.27.7. Strategy Overview 20.4.27.7.1. Marketing Strategy 20.4.27.7.2. Product Strategy 20.4.27.7.3. Channel Strategy 20.4.28. Fujirebio 20.4.28.1. Overview 20.4.28.2. Product Portfolio 20.4.28.3. Key Financials 20.4.28.4. SWOT Analysis 20.4.28.5. Key Developments 20.4.28.6. Sales Footprint 20.4.28.7. Strategy Overview 20.4.28.7.1. Marketing Strategy 20.4.28.7.2. Product Strategy 20.4.28.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Prostate-Specific Antigen Testing Market
